| 20.94 0.14 (0.67%) | 06-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.8  |
1-year : | 31.38 |
| Resists | First : | 23.8 |
Second : | 26.87 |
| Pivot price | 20.75 |
|||
| Supports | First : | 18.85 | Second : | 15.68 |
| MAs | MA(5) : | 20.48  |
MA(20) : | 21.48 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.8 |
Signal : | 0 |
| %K %D | K(14,3) : | 31.1 |
D(3) : | 27 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 27.2 | Low : | 18.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALMR ] has closed below upper band by 45.7%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 21.52 - 21.58 | 21.58 - 21.66 |
| Low: | 20.41 - 20.49 | 20.49 - 20.57 |
| Close: | 20.8 - 20.92 | 20.92 - 21.05 |
Alamar Biosciences is a commercial-stage proteomics company focused on ultra-sensitive, multiplexed protein detection for research and future clinical applications. Its platform combines proprietary instruments, consumables, and software to provide an end-to-end system for measuring multiple low-abundance proteins across research and potential clinical applications.
Tue, 02 Jun 2026
Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics - The Manila Times
Thu, 14 May 2026
Evaluating Alamar Biosciences (ALMR) Valuation As Shares Show Modest Year To Date Gains - Yahoo Finance
Tue, 12 May 2026
Alamar Biosciences, Inc. (ALMR) Market Cap - Zacks Investment Research
Sun, 10 May 2026
Alamar Biosciences Revenue Jump And IPO Spotlight Neuro Focus Potential - simplywall.st
Fri, 08 May 2026
Fresh off a $220M IPO, Alamar expands neuro tests and posts $26M quarter - Stock Titan
Sun, 19 Apr 2026
Alamar Biosciences: Looking For An Early Detection - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 26.6 (%) |
| Held by Institutions | 28.3 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -0.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.57 |
| Profit Margin | -49.9 % |
| Operating Margin | -47.5 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 98.9 % |
| Gross Profit (p.s.) | 0.71 |
| Sales Per Share | 1.25 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -32.22 |
| PEG Ratio | 0 |
| Price to Book value | -8.15 |
| Price to Sales | 16.65 |
| Price to Cash Flow | -23.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|